CBIO CRESCENT BIOPHARMA INC. revenue, earnings and financials
For the quarter ended June 30, 2026, CRESCENT BIOPHARMA INC. reported revenue of $0, net income of −$24.8M and diluted EPS of n/a; for the fiscal year ended December 2025 revenue was $10.8M.
CBIO annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $10.8M, gross profit n/a, operating income −$153M, net income $154K (margin 1.4%), EPS n/a
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$40.0M, net income $37.9K (margin n/a), EPS −$0.59
- Fiscal year ended Dec 2023: revenue $10.0K, gross profit n/a, operating income −$39.3M, net income $36.9K (margin 369.0%), EPS −$0.58
- Fiscal year ended Dec 2022: revenue $75.0K, gross profit n/a, operating income −$47.4M, net income −$46.7M (margin -62251.7%), EPS −$0.89
- Fiscal year ended Dec 2021: revenue $1.16M, gross profit n/a, operating income −$63.4M, net income −$63.4M (margin -5469.0%), EPS −$1.23
CBIO quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $0, net income −$24.8M, EPS n/a
- Quarter ended Mar 31, 2026: revenue $1.04M, net income −$23.3M, EPS n/a
- Quarter ended Dec 31, 2025: revenue n/a, net income −$23.3M, EPS n/a
- Quarter ended Sep 30, 2025: revenue n/a, net income −$24.6M, EPS n/a
- Quarter ended Jun 30, 2025: revenue $0, net income −$21.8M, EPS n/a
- Quarter ended Mar 31, 2025: revenue $0, net income −$15.1M, EPS n/a
- Quarter ended Dec 31, 2024: revenue $0, net income −$17.9M, EPS −$0.24
- Quarter ended Sep 30, 2024: revenue n/a, net income −$9.82M, EPS −$0.15
- Quarter ended Jun 30, 2024: revenue n/a, net income −$10.1M, EPS −$0.16
- Quarter ended Mar 31, 2024: revenue n/a, net income −$10.7M, EPS −$0.04
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income $27.9M, EPS −$0.14
- Quarter ended Sep 30, 2023: revenue n/a, net income −$9.20M, EPS −$0.14
- Quarter ended Jun 30, 2023: revenue n/a, net income −$8.26M, EPS −$0.13
- Quarter ended Mar 31, 2023: revenue n/a, net income −$10.4M, EPS −$0.17
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$10.2M, EPS −$0.20
- Quarter ended Sep 30, 2022: revenue n/a, net income −$8.52M, EPS −$0.16
- Quarter ended Jun 30, 2022: revenue $75.0K (up 52716.9% year over year), net income −$13.3M, EPS −$0.25
- Quarter ended Mar 31, 2022: revenue n/a, net income −$14.7M, EPS −$0.28
- Quarter ended Dec 31, 2021 (from the annual report): revenue $17.6K, net income −$17.4M, EPS −$0.33
- Quarter ended Sep 30, 2021: revenue $86.6K, net income −$17.3M, EPS −$0.34
CBIO cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$71.5M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$31.1M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$34.9M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$46.5M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$57.5M, share buybacks n/a
CBIO balance sheet
- Jun 30, 2026: cash $172M, total assets $183M, total liabilities $19.5M, shareholders' equity $163M
- Mar 31, 2026: cash $189M, total assets $199M, total liabilities $15.3M, shareholders' equity $184M
- Dec 31, 2025: cash $213M, total assets $240M, total liabilities $37.3M, shareholders' equity $203M
- Sep 30, 2025: cash $133M, total assets $138M, total liabilities $21.6M, shareholders' equity $117M
- Jun 30, 2025: cash $153M, total assets $157M, total liabilities $18.2M, shareholders' equity $139M
- Mar 31, 2025: cash $22.4M, total assets $5.99M, total liabilities $2.62M, shareholders' equity −$30.2M
- Dec 31, 2024: cash $34.8M, total assets $35.6M, total liabilities $47.1M, shareholders' equity −$15.5M
- Sep 30, 2024: cash $14.4M, total assets $15.7M, total liabilities $4.32M, shareholders' equity −$1.30M
What is CBIO's revenue?
CRESCENT BIOPHARMA INC. reported $10.8M of revenue for the fiscal year ended December 2025.
Is CBIO profitable?
No. CRESCENT BIOPHARMA INC. lost $96.0M over the last four quarters.